Because GROα plays an important role in tumor progression by stimulating angiogenesis and metastasis, DK-139 was proposed as a potential drug candidate for the inhibition of tumor cell locomotion and invasion via the suppression of NF-κB-mediated GROα expression [11,179]. This evidence concerns the gene CXCL1 and neoplasm.